Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Antiviral Res. 2017 Oct;146:164-173. doi: 10.1016/j.antiviral.2017.09.005. Epub 2017 Sep 8.
Zika virus (ZIKV) is rapidly spreading throughout the Americas and is associated with significant fetal complications, most notably microcephaly. Treatment with polyclonal antibodies for pregnant women at risk of ZIKV-related complications could be a safe alternative to vaccination. We found that large quantities of human polyclonal antibodies could be rapidly produced in transchromosomal bovines (TcB) and successfully used to protect mice from lethal infection. Additionally, antibody treatment eliminated ZIKV induced tissue damage in immunologically privileged sites such as the brain and testes and protected against testicular atrophy. These data indicate that rapid development and deployment of human polyclonal antibodies could be a viable countermeasure against ZIKV.
寨卡病毒（ZIKV）正在迅速在美洲传播，并与严重的胎儿并发症相关，尤其是小头畸形。对于有感染寨卡病毒相关并发症风险的孕妇，使用多克隆抗体治疗可能是疫苗接种的安全替代方法。我们发现大量的人源多克隆抗体可以在转染色体牛（TcB）中快速产生，并成功地用于保护小鼠免受致命感染。此外，抗体治疗消除了 ZIKV 在免疫豁免部位（如大脑和睾丸）引起的组织损伤，并防止了睾丸萎缩。这些数据表明，快速开发和部署人源多克隆抗体可能是对抗 ZIKV 的可行对策。
